Publications

5808 Results

Circulating tumor cells (CTCs) in SWOG S1216: a phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC)

Authors
A Goldkorn;M Plets;N Agarwal;M Hussain;P Lara;D Vaena;G MacVicar;T Crispino;A Harzstark;P Twardowski;C Tangen;C Hugen;T Xu;Y Xu;J Pinski;S Ingles;C Higano;N Vogelzang;I Thompson;D Quinn
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 11516); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster discussion
Year
2016
Research Committee(s)
Genitourinary
Study Number(s)
S1216

SWOG S1404: A phase III randomized trial comparing high dose interferon to pembrolizumab in patients with high risk resected melanoma

Authors
K Grossman;M Othus;A Tarhini;SP Patel;J Moon;V Sondak;JM Kirkwood;A Ribas
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr e21032); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), publication only
Year
2016
Research Committee(s)
Melanoma
Study Number(s)
S1404

SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as therapy for resectable pancreatic adenocarcinoma

Authors
D Sohal;K Guthrie;S Ahmad;N Gandhi;M Shaalan Beg;A Wang Gillam;S McDonough;A Lowy;P Philip;H Hochster
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr TPS4151); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL) TIP, poster session
Year
2016
Research Committee(s)
Gastrointestinal
Study Number(s)
S1505

Randomized trial of medroxyprogesterone acetate for prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630 (ClinicalTrials.gov NCT00002920)

Authors
K Albain;J Unger;R Livingston;K Crew;S Wilczynski;C Salomon;BL Smith;L Wong;DL Campbell;D Einspahr;G Anderson;D Hershman;G Goodman;PH Brown;F Meyskens;R Potkul
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 547); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Breast
Study Number(s)
S9630

Biomarker-enriched efficacy of cetuximab-based therapy: squamous subset analysis from SWOG S0819, a phase III trial of chemotherapy with or without cetuximab in advanced NSCLC

Authors
F Hirsch;M Redman;R Herbst;E Kim;T Semrad;L Bazhenova;G Masters;K Oettel;P Guaglianone;C Reynolds;A Karnad;S Arnold;M Varella Garcia;J Moon;P Mack;C Blanke;K Kelly;D Gandara
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 9090); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Lung
Study Number(s)
S0819

A genome-wide association study (GWAS) of survival in metastatic breast cancer (MBC) patients treated with letrozole (L) with or without bevacizumab (B) in CALGB 40503

Authors
F Innocenti;K Owzar;C Jiang;A Sibley;F Mulkey;L Carey;D Tripathy;W Barry;E Winer;C Hudis;H McLeod;M Dickler
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 538); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Breast
Study Number(s)
CTSU/C40503

Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa)

Authors
M Pomerantz;V Wang;P Kantoff;W Xie;M Kohli;G-S M Lee;E Wang;Y-H Chen;N Hahn;D Jarrard;G Liu;J Garcia;M Carducci;R DiPaola;M Freedman;C Sweeney
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 1540); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/E3805

Intergroup randomized phase III study of postoperative oxaliplatin, 5-fluorouracil and leucovorin (mFOLFOX6) vs oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (Bev) for patients (pts) with stage II or III rectal cancer receiving pre-operative chemoradiation: E5204 coordinated by the Eastern Cooperative Oncology Group

Authors
AB Benson;N Meropol;P Catalano;F Zhao;E Sigurdson;A Chakravarthy;S Hamilton;P Flynn;K Kiel;C Leichman;N Petrelli;F Sinicrope;J Tepper;J Sloan;J Meyerhardt;L Wagner;P O'Dwyer
Journal / Conference
Journal Clinical Oncology 34, 2016 (suppl; abstr 3616); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/E5204

Identifying risk factors for toxicity in patients with hormone-receptor positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (Alliance) correlative study

Authors
D Li;M Dickler;L McCall;O Hahn;C Hudis;H Cohen;HB Muss;K Ballman;W Winer;D Tripathy;C Cirrincione;W Barry;A Hurria
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 10047); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), poster session
Year
2016
Research Committee(s)
Breast
Study Number(s)
CTSU/C40503

Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)

Authors
G Abou-Alfa;D Niedzwieski;J Knox;A Kaubisch;J Posey;B Tan;P Kavan;K Goel;P Lammers;T Bekaii-Saab;V Tam;L Rajdev;R Kelley;A Siegel;J Balletti;J Harding;L Schwartz;R Goldberg;M Bertagnolli;A Venook
Journal / Conference
Journal of Clinical Oncology 34, 2016 (suppl; abstr 4003); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation
Year
2016
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80802